Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

Figure 1

Treatment recommendations for EGFRI-associated rash. Adapted from Lynch et al. 2007 [45].